SRPK2 Phosphorylates Tau and Mediates the Cognitive Defects in Alzheimer's Disease

Yi Hong, Emory University
Chi Bun Chan, Emory University
Il-Sun Kwon, Emory University
Xuekun Li, Emory University
Mingke Song, Emory University
Hyun-Pil Lee, Case Western Reserve University
Xia Liu, Emory University
Pradoldej Sompol, Emory University
Peng Jin, Emory University
Hyoung-gon Lee, Case Western Reserve University

Only first 10 authors above; see publication for full author list.

Journal Title: Journal of Neuroscience Nursing
Volume: Volume 32, Number 48
Publisher: Society for Neuroscience | 2012-11-28, Pages 17262-17272
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1523/JNEUROSCI.3300-12.2012
Permanent URL: http://pid.emory.edu/ark:/25593/f3mc1

Final published version: http://www.jneurosci.org/content/32/48/17262

Copyright information:
© 2012 the authors

Accessed December 25, 2019 7:20 PM EST
SRPK2 Phosphorylates Tau and Mediates the Cognitive Defects in Alzheimer’s Disease

Yi Hong1, Chi Bun Chan1,*, Il-Sun Kwon1, Xuekun Li2, Mingke Song3, Hyun-Pil Lee4, Xia Liu1, Pradoldej Sompol1, Peng Jin2, Hyoung-gon Lee4, Shan Ping Yu3, and Keqiang Ye1,*

1Department of Pathology and Laboratory Medicine Emory University School of Medicine 615 Michael Street, Atlanta, GA 30322
2Department of Human Genetics Emory University School of Medicine 615 Michael Street, Atlanta, GA 30322
3Department of Anesthesiology Emory University School of Medicine 615 Michael Street, Atlanta, GA 30322
4Department of Pathology; Case Western Reserve University School of Medicine; 2103 Cornell Road, Cleveland, OH 44106

Abstract
Serine-arginine protein kinases 2 (SRPK2) is a cell cycle-regulated kinase that phosphorylates serine/arginine domain-containing proteins and mediates pre-mRNA splicing with unclear function in neurons. Here, we show that SRPK2 phosphorylates tau on S214, suppresses tau-dependent microtubule polymerization and inhibits axonal elongation in neurons. Depletion of SRPK2 in dentate gyrus inhibits tau phosphorylation in APP/PS1 mouse and alleviates the impaired cognitive behaviors. The defective LTP in APP/PS1 mice is also improved after SRPK2 depletion. Moreover, active SRPK2 is increased in the cortex of APP/PS1 mice and the pathological structures of human Alzheimer’s disease (AD) brain. Therefore, our study suggests SRPK2 may contribute to the formation of hyperphosphorylated tau and the pathogenesis of AD.

INTRODUCTION
Neuronal morphology is tightly controlled by the dynamic assembly and disassembly of microtubule cytoskeleton network, which is supported and regulated by microtubule associated proteins (MAPs). Tau is a core MAP that predominantly localizes in axons. It contains three functional domains: an amino-terminal projection domain, a carboxyl-terminal domain of microtubule-binding repeats and a short tail sequence (Ittner and Gotz, 2011). The major functions of tau are stabilization of microtubules and regulation of motor-driven axonal transport (Gotz et al., 2006). Binding of tau with microtubule is regulated by its phosphorylation status, which changes its structural morphology and causes its dissociation from microtubule to form the paired helical filament (PHF) (Billingsley and Kincaid, 1997; Dolan and Johnson, 2010). As a result, the microtubule network is disrupted in pathological conditions like Alzheimer’s disease (AD) in which tau is abnormally phosphorylated (Martin et al., 2011).

Serine-arginine protein kinases (SRPK) is a family of cell cycle-regulated kinases that phosphorylate serine/arginine (SR) domain-containing proteins in the nuclear speckles to

*All correspondence should be addressed to: Drs. Chi Bun Chan (cbchan@emory.edu) and Keqiang Ye (kye@emory.edu).

The authors declare no competing financial interests.
mediate pre-mRNA splicing (Giannakouros et al., 2011). They also regulate the subcellular localization of splicing factors SF2/ASF through phosphorylating these proteins (Koizumi et al., 1999). In addition to the major function as a SR protein kinase, SRPK2 is involved in the cell cycle regulation, cell proliferation, and apoptosis (Jang et al., 2009; Giannakouros et al., 2011). The two SRPK paralogs (SRPK1 and SRPK2) have different tissue specificity that SRPK1 is predominantly expressed in pancreas, whereas SRPK2 is enriched in the brain, although both are also co-expressed in other peripheral tissues (Wang et al., 1999). The brain-enriched expression of SRPK2 implies that it may play an important role in controlling neuronal functions. In agreement with this notion, we have previously shown that Akt phosphorylates SRPK2 on T492 and elicits its binding to 14-3-3, which mediates cell cycle progression and cell death in neurons (Jang et al., 2009). Moreover, we found that SRPK2 is a caspase substrate, which promotes neuronal apoptosis after caspase cleavage (Hong et al., 2011).

In this study, we demonstrate that that activity of SRPK2 is focally enhanced in both human and rodent brains of AD, implying SRPK2 is correlated with AD progression. Depleting SRPK2 in the hippocampus alleviates the memory defect and improves the induction of long-term potentiation in APP/PS1 mice. SRPK2 also phosphorylates tau on S214 and suppresses microtubule polymerization. Our finding that SRPK2 phosphorylates tau and is activated in AD neurons suggests SRPK2 is implicated in the pathogenesis of AD.

MATERIALS AND METHODS

Reagents

Anti-myc and anti-APP antibodies were purchased from Cell Signaling. Anti-Tau-1 antibody was from Millipore. Anti-phospho-Tau S214 antibody and Aβ1-42 ELISA kit were from Invitrogen. Anti-SRPK2 antibody was from BD Bioscience. Anti-phospho-SRPK2 T492 antibody was generated by immunizing rabbit with the phospho-peptide, and the resulting serum was affinity purified with the phospho-peptide conjugated onto the affigel. Anti-phosphorylated Tau antibody (AT8) was purchased from Pierce. Anti-tubulin antibody, 4,6-diamidino-2-phenylindole (DAPI), Aβ1-42, and Thioflavin-S were from Sigma-Aldrich. Aβ1-42 fibrils were produced by dissolving the lyophilized peptide in H2O and incubated at 37 °C for 3 days as reported (Lorenzo and Yankner, 1994). Glutathione Sepharose 4B was purchased from GE Healthcare. [γ-32P]-ATP was from Perkin Elmer. PKA, CDK5 and GSK inhibitors were from Calbiochem. Bovine Tubulin protein was purchased from Cytoskeleton. SRPK inhibitor (SRPIN340) was from Maybridge.

Plasmids

The coding sequence of human SRPK2 was inserted into pFUGW between Xba I and Mfe I or into pEGX-4T-2 between Sal I and Not I. Tau fragments were inserted into pEGX-4T-2 vector between Sal I and Not I. The shRNA sequences targeting SRPK2 were fused into the lentiviral vector pFH1UGW. The sites indicated for tau protein represent the amino acids in the longest form of human tau protein (Tau441). The target sequences recognized by shSRPK2 (5′-GCAGAGAGTGATTACACGTAT-3′) were acquired from Sigma-Aldrich MISSION shRNA library.

Cell culture and transient transfection

HEK293 and HEK293FT cells were maintained in DMEM supplemented with 10% fetal bovine serum, 2 mg/ml glutamine, and 100 U penicillin–streptomycin at 37 °C in a humidified incubator containing 5% CO2. Primary rat cortical and hippocampal neurons were cultured as previously described (Jang et al., 2009). Transfection of HEK293FT cells for lentivirus packaging was performed using calcium phosphate precipitation method.
Transfection of primary neuron was carried out using Lipofectamine 2000™ (Invitrogen) according to the manufacturer’s instructions. Twenty-four hours after transfection, cells were fixed with 4% PFA, immunostained with anti-Tau-1 antibody, and analyzed using fluorescent microscopy. On average, 20 cells per transfection were counted. The length of the primary neurite was measured using Image J software from NIH.

**In Vitro Kinase Assay**

GST-tagged SRPK2 proteins and Tau proteins were expressed in *E. coli* and purified with the Glutathione Sepharose™ 4B Beads. Purified SRPK2 proteins (1 μg/each) were incubated with tau proteins (1 μg/each) in kinase reaction buffer (25 mM Tris, pH 7.5, with 10 mM MgCl2, 2 mM DTT, 5 mM β-Glycerolphosphate, 0.1 mM Na3VO4, and 2 mM EGTA) containing 20 μM ATP and 1 μCi of [γ-32P]-ATP for 30 min at 30 °C. Reactions were then separated in SDS-PAGE and analyzed by autoradiography.

**Immunoprecipitation and Western blot analysis**

Cells were washed with ice-cold PBS and lysed in Co-immunoprecipitation (Co-IP) buffer (50 mM Tris–HCl [pH 7.5], 150 mM NaCl, 1% Nonidet P-40, 5 mM EDTA, 5 mM EGTA, 15 mM MgCl2, 60 mM β-glycerophosphate, 0.1 mM sodium orthovanadate, 0.1 mM NaF, 0.1 mM benzamide, 10 μg/ml aprotinin, 10 μg/ml leupeptin and 1 mM PMSF) at 4 °C for 2 h with rotation. Detergent insoluble materials were removed by centrifugation, and CoIP was performed as before (Chi et al., 2009). Immunoprecipitated proteins separated by SDS-PAGE and then transferred to a nitrocellulose membrane. The membrane was blocked with TBS containing 5% nonfat milk and 0.1% Tween 20 (TBST) at RT for 1 h, followed by the incubation with primary antibody at 4 °C overnight, and with the secondary antibody at RT for 1 h. After washing with TBST, the membrane was developed using the enhanced chemiluminescent (ECL) detection system.

**Microtubule polymerization assay**

Recombinant Tau was incubated with GST, GST-SRPK2, or GST-SRPK2-KD for *in vitro* phosphorylation at 37 °C for 1 h, prior to the incubation with tubulin. The *in vitro* microtubule polymerization assay was performed using 1.5 μM tau and 20 μM tubulin as reported before (Yoshida and Goedert, 2006).

**Analysis of Tau aggregation**

Tau aggregation was detected as previously described (Zhang et al., 2006). Briefly, rat neurons were isolated from E17 fetus and cultured for 10 days. The cells were then infected with various lentiviruses for 48 h, followed by homogenization in breaking buffer (0.25 M sucrose; 10 mM HEPES, pH 7.2; 1 mM MgOAc2; protease inhibitor cocktail). Cytosol was prepared from postnuclear supernatant by ultracentrifugation for 1 h at 190,000 g. The resulting membrane pellet was resuspended and incubated on ice for 30 min with 5 μM nocodazole, followed by ultracentrifugation for 1 h at 190,000 g to produce postnocodazole supernatants containing the microtubule-associated tau. The generated pellets containing both membrane-associated and aggregated tau were further extracted using 100 mM sodium carbonate buffer (pH 11.5) at 4 °C for 30 min. The post-Na2CO3 pellets were prepared by ultracentrifugation at 190,000 g for 1 h and washed with 1% SDS to produce a fraction containing tau aggregates. All the fractions were quantified for equal amount of protein, separated with SDS-PAGE, and detected with anti-Tau-1 antibody and anti-pS214 Tau antibody.
**Lentivirus packaging**

Lentivirus packaging system (pFUGW or pFH1UGW, pCMVΔR8.92, and pVSVG) was acquired from the Viral Core Facility of Emory University. Transfection of the lentiviral vectors were performed in HEK293FT cells (50%-60% confluent) with calcium phosphate reagents. After 16 h, the transfection media were discarded, and the cells were washed with sterile PBS and incubated with pre-warmed fresh culture media. After 48 h incubation, the cell culture media were collected, and the lentiviral particles were concentrated by ultracentrifugation at 22,000 RPM (SW28) for 2 hrs at 4 °C. All the lentivirus-containing materials were handled according to the Biosafety regulation of Emory University.

**Stereotaxic injection of Lentivirus in mouse dentate dyrus (DG)**

*In vivo* lentiviral grating was performed as described previously (Szulwach et al., 2010) with a few modifications. In brief, 12-month-old WT and APP/PS1 male mice were anesthetized with hydrochloride, and lentivirus (LV, 2.5 μl with titer >1×10^8/ml) was injected stereotaxically into the DG using the following coordinates relative to bregma: anteroposterior, −(1/2) × d mm; lateral, ±1.8 mm (if d > 1.6), or otherwise ±1.7 mm; and ventral, −1.9 mm (from dura).

**Human brain tissue**

Using a protocol approved by the Case Western Reserve University IRB, human brain tissue was obtained post-mortem and fixed in either routine formalin or methacarn (methanol:chloform:acetic acid; 6:3:1 v/v/v), dehydrated through ascending ethanol, embedded in paraffin, cut into 5 μm sections, and mounted on saline-coated slides. The ages of control cases were similar to the cases with the AD cases used in this study.

**Immunohistochemistry**

Immunohistochemistry was performed by using the peroxidase antiperoxidase protocol. Briefly, tissue sections were deparaffinized in xylene, hydrated through descending ethanol, and endogenous peroxidase activity was eliminated by incubation in 3% hydrogen peroxide in methanol for 5 min. After antigen-retrieval in boiling sodium citrate buffer (10 mM), the sections were incubated with primary antibodies (anti-phospho-SRPK2 T492; 1:500, anti-phospho-Tau S214; 1:100 and anti-PHF Tau (AT8) 1: 500) for overnight at 4 °C. The signal was developed using Histostain-SP kit (Invitrogen)

For the double immunofluorescence staining, the sections were incubated overnight at 4 °C with a mixture of rabbit anti-phospho-SRPK2 T472 and mouse anti-PHF-Tau AT8. After being washed with TBS, the sections were incubated with a mixture of Alexa Fluor 488- and 568-coupled secondary antibodies (Invitrogen) for detection. Images were acquired through an AxioCam camera on an Axiovert 200M microscope (Zeiss). Images were then analyzed with the Axiovision software (Zeiss).

**Morris Water Maze**

Morris water maze was carried out as previously described (Lee et al., 2010). Acquisition training consisted of 5 test d with four daily trials. Mice entered the maze facing the wall and began each trial at a different entry point in a semi-random order. Trials lasted 60 s or until the animal mounted the platform with a 15-min inter-trial interval. A probe trial was conducted on day 6 wherein the platform was removed, and the animal swam for 60 s and the time spent in the target quadrant (NW) versus the adjacent and opposite quadrants was recorded. A video camera mounted above the swim arena and linked to TopScan software recorded swim distance, swim speed and time to platform and was used for tracking and analysis.
Electrophysiological Analysis

The mice were anaesthetized with isoflurane, decapitated, and their brains were removed into ice-cold artificial cerebrospinal fluid (ACSF) containing: 124 mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 6.0 mM MgCl2, 26 mM NaHCO3, 2.0 mM CaCl2, and 10 mM glucose. ACSF was saturated with 95% O2 and 5% CO2, at pH 7.4. Hippocampus was dissected out on an ice-cold base plate and cut into 400μm thick transverse slices with a vibratome (Vibratome 1000 Plus Sectioning System, St Louis, MO). Slices were collected with a soft brush, incubated at room temperature (23-24 °C) in ACSF for 60-90 min before recording. For electrophysiological recording, Hippocampal slices were transferred to a small recording chamber (RC-22C, Warner Instruments) on a fixed-stage microscope (Olympus CX-31, Tokyo, Japan) and superfused with normal ACSF at the rate of 3 ml per min with ACSF at 23-24 °C. For the recording of field excitatory post-synaptic potentials (fEPSPs), a glass microelectrode filled with ACSF with resistance of 3-4 MΩ was placed in CA3 region, and a 0.1 MΩ tungsten monopolar electrode was used to stimulate the dentate gyrus of hippocampus. The stimulation output (Master-8; AMPI, Jerusalem, Israel) was controlled by the trigger function of EPC9 amplifier (HEKA Elektronik, Lambrecht, Germany). fEPSPs were recorded in current-clamp mode of EPC9. Data were filtered at 3KHz and digitized at sampling rates of 20 KHz using Pulse software (HEKA Elektronik). In all experiments the stimulus intensity (0.2 ms duration, 30-60 μA) was set to evoke 40% of the maximum fEPSP initial slope and the test pulse was applied at a rate of 0.033 Hz. Paired-pulse facilitation (PPF) was examined by applying pairs of pulses which were separated by 10-500 ms different intervals. To induce tetanus long-term potentiation (LTP) at the mossy fiber-CA3 synapse, one stimulus train of 100 pulses at 100Hz was applied. The magnitude of LTP was expressed as the mean percentage of baseline fEPSP initial slope.

Statistical analysis

Data were expressed as mean ± S.E.M. All statistical calculations were carried out with the software Prism (GaphPad) by ANOVA. P < 0.05 was considered statistically significant. Results were calculated from at least three independent experiments.

RESULTS

SRPK2 is activated in AD neurons

In search for new SRPK2 functions in the nervous system, we found that the activity of SRPK2 (as revealed by T492 phosphorylation) (Jang et al., 2009) was significantly increased in the brain of APP/PS1 transgenic mouse, an established animal model of AD that overexpresses mutant forms of amyloid precursor protein (APP) and presenilin (PS) (Trinchese et al., 2004), than the age-matched wild-type control (Fig 1A). This elevated SRPK2 activity could be detected in APP/PS1 cortical neurons as early as 4 months of age (Fig 1B). Similar observation was made in another transgenic mouse model that expresses APPTg2576, PS1M146V and TauP301L (3xTg-AD) (Oddo et al., 2003). As shown in Fig 1C and D, phospho-SRPK2 T492 positive cells were found in CA1 neurons, where they paralleled with the tau in the paired-helical filament (PHF-tau) as detected by the AT8 antibody (Spillantini et al., 1996) (Fig 1E). In double immunofluorescence staining, phospho-SRPK2 T492 was found in of AT8 positive neuronal cells in 3xTg-AD brain (n=3) (Fig 1F). SRPK2 T492 phosphorylation was also 19.1 ± 6.7% increased in human AD brains, which was co-localized with neurofibrillary tangles (NFT), granulovacuolar degeneration (GVD) and Hirano body (Fig 1G to 1I). Moreover, the phospho-SRPK2 T492 signals co-localized with the PHF-tau in the human AD brains (Fig 1J). Thus, our results imply that neuronal SRPK2 is activated during the pathological process of AD in both human and mouse brains.
Depletion of SRPK2 improves the synaptic plasticity in APP/PS1 mice

If SRPK2 is implicated in the pathological progression of AD, suppressing its expression should alleviate the clinical syndromes. We therefore investigated whether SRPK2 silencing reduced learning and memory impairments in AD mice since memory deterioration is one of the behavioral hallmarks of AD (Sperling et al., 2010). Control lentivirus (LV-GFP) or virus overexpressing shSRPK2 (LV-shSRPK2) was bilaterally injected into the DG of WT or APP/PS1 mice at the age of 14 months when the β-amloid (Aβ) plaque was stably formed (data not shown). This lentivirus can effectively infected the DG neurons (Fig 2A) and suppress SRPK2 expression (Fig 2B). Morris water maze test was then carried out to test the memory of the virus-infected WT or APP/PS1 mice. As illustrated in Fig 2C, APP/PS1 mice spent lesser time in the platform quadrant (35.3 ± 6.0% vs 22.6 ± 3.6%), which was significantly reversed in the LV-shSRPK2-injected mice (22.6 ± 3.6% vs 31.9 ± 3.1%). The performance of WT mice injected with LV-shSRPK2 was not significantly altered when compared with the LV-GFP-injected WT mice (35.3 ± 6.0% vs 31.3 ± 4.3%). The result implies that ablating SRPK2 expression may improve the learning and memory in APP/PS1 but not WT mice. To further delineate how SRPK2 depletion leads to memory amelioration, we investigated electrophysiological changes of single neurons by inducing long-term potentiation (LTP) at the mossy fiber-CA3 synapse of APP/PS1 mice infected with various lentiviruses. As shown in Fig 2D, the LTP magnitude was markedly suppressed in LV-GFP-injected APP/PS1 mice when compared with the LV-GFP-injected WT mice. In contrast, the LTP magnitude in APP/PS1 mice was significantly elevated after LV-shSRPK2 infection (133.9 ± 8.84% vs 156.9 ± 9.11% of baseline, P< 0.05, n=6), suggesting a definite enhancement in synaptic plasticity after SRPK2 depletion. Paired pulse facilitation (PPF), an indication of presynaptic function, was also examined at an interpulse interval from 10 to 500 ms (Fig 2E). The averaged PPF amplitude in LV-GFP-injected APP/PS1 mice (87.7 ± 14.25%, n=6) was lower than the LV-GFP-injected WT mice (106.2 ± 20.1%, n=6), but was significantly increased after LV-shSRPK2 infection (227.4 ± 81.1%, n=6, P< 0.01). These results suggest a rescued and improved presynaptic function after SRPK2 knockdown in the DG region of hippocampus.

SRPK2 interacts with tau

Accumulation of phosphorylated tau aggregates in the dendrite of neurons damages synaptic plasticity in AD mouse models (Yoshiyama et al., 2007; Hoover et al., 2010). Given that SRPK2 depletion ameliorated the memory defect of APP/PS1 mice, we thus hypothesized that SRPK2 might modulate the function of tau. Therefore, we tested if SRPK2 associated with tau. As shown in Fig 3A, endogenous SRPK2 bound tau in SH-SY5Y neuroblastoma cells. A similar observation was made in brain lysates from normal and APP/PS1 mice, which showed that both SRPK1 and SRPK2 interacted with tau (Fig 3B). GST pull-down assay provided a direct interaction between tau and SRPKs (Fig 3C). To further characterize the SRPK2/tau interaction, we used a series of tau or SRPK2 truncates to explore the binding regions between the two proteins (Fig 3D and 3F). In vitro binding assay showed that SRPK2 bound to the proline-rich region [amino acid (aa) 191-250] of tau (Fig 3E) through its aa sequence 384-438, a region within the spacer between the two kinase domains (Fig 3F). Together, these results indicate that SRPK2 is a novel interaction partner of tau in neurons.

Tau is a substrate of SRPK2

In HEK293 cells, we found that over-expression of wild-type (SRPK2 WT) but not the kinase-dead (SRPK2 KD) SRPK2 reduced the mobility of tau in SDS-PAGE, suggesting that tau phosphorylation might be increased in the presence of active SRPK2 (Fig 4A). To verify whether SRPK2 could phosphorylate tau directly, we conducted an in vitro kinase assay. SRPK2 WT exhibited strong autophosphorylation and potently phosphorylated tau.
which were totally abolished when SRPK2 KD was used (Fig 4B, lanes 1 and 2). Our previous study shows that the phosphorylation status of SRPK2 on T492 by Akt regulates its kinase activity in which the T492D mutant of SRPK2 displays higher kinase activity, whereas T492A mutation inhibits the activity (Jang et al., 2009). Accordingly, SRPK2 T492D exhibited more robust autophosphorylation (band intensity: 1.0 vs 1.61) and stronger phosphorylation on tau (band intensity: 1.0 vs 1.34) than SRPK2 WT, while SRPK2 T492A showed an impaired autophosphorylation (band intensity: 1.0 vs 0.48) and weaker kinase activity towards tau (band intensity: 1.0 vs 0.86) (Fig 4B). To identify the aa residues that are phosphorylated by SRPK2, we prepared various tau truncation mutants for in vitro kinase assay (Fig 4C). We found that aa 191-250 in tau could be phosphorylated by SRPK2 (Fig 4D). Further structural analysis of this region revealed three serines (S208, S210 and S214) in the SR repeats, which represented the potential phosphorylation site for SRPK protein kinases (Fig 4E). We thus prepared point mutants of these serine residues to pinpoint the SRPK2 phosphorylation site. While the tau S214A mutation fully abolished the phosphorylation by SRPK2, mutation of the other serine residues (S208, S210) lacked the effect (Fig 4F).

To explore whether SRPK2 could phosphorylate tau in neurons, we over-expressed SRPK2 in primary neuron cultures using lentivirus overexpressing wild-type SRPK2 (LV-myc-SRPK2 WT) or kinase-dead SRPK2 (LV-myc-SRPK2 KD). Immunoblotting assay showed that overexpression of SRPK2-WT potently increased, whereas SRPK2-KD reduced, tau S214 phosphorylation in neurons (Fig 4G). To further study the effect of SRPK2 on tau phosphorylation, we infected primary mouse neurons with control lentivirus (LV-con shRNA) or lentivirus expressing shRNAs against SRPK2. LV-shSRPK2 effectively knocked down SRPK2 in mouse neurons and downregulated phospho-tau S214 (Fig 4H, 1st and 2nd panels). In cultured primary neurons, SRPK2 predominantly localized in the cell body and neurites and overexpression of SRPK2 strongly enhanced the phosphorylation of tau on S214 (Fig 4I). In contrast, knockdown of SRPK2 expression evidently inhibited tau S214 phosphorylation (Fig 4J). To compare the relative contribution of SRPK2 with other kinases that also phosphorylate tau on S214, we inhibited protein kinase A (PKA), cyclin dependant kinase 5 (CDK5) and glycogen synthase kinase 3 (GSK3) with small inhibitors (H89, roscovitine and SB216763 respectively) in cultured neurons to monitor the tau phosphorylation in response to SRPK2 overexpression. In control virus-infected cells, inhibition of PKA or GSK3 significantly reduced tau S214 phosphorylation (Fig 4K). SRPK2 overexpression resulted in robust tau S214 phosphorylation even in the presence of PKAand CDK5 inhibitors. However, tau S214 phosphorylation was not increased after SRPK2 overexpression when GSK3 was inhibited (Fig 4K). Together, these results suggest that tau is a substrate of SRPK2 and S214 is the major phosphorylation residue.

**SRPK2 mediates tau phosphorylation in vivo**

We next tested if SRPK2 is critical in mediating tau S214 phosphorylation in APP/PS1 mice. The number of phospho-tau S214 positive neuron in DG was greatly enhanced in APP/PS1 mice (Fig 5A, lower left panel). Depletion of SRPK2 reduced the phoshpo-Tau S214 level in the APP/PS1 DG region (Fig 5A, lower right panel), whereas as the virus did not show any impact on phospho-tau S214 level on WT mice (Fig 5A, upper panels). Tau S214 phosphorylation level was also comparable between the LV-GFP-injected WT mice and those mice without any virus injection. Apoptotic cells (as revealed by the presence of active caspase 3) could be readily detected in the DG of APP/PS1 mice (1.5 ± 0.32 % of neurons in DG, n=3) (Fig 5B, lower left panel), which fits with the previous observation that apoptosis was enhanced in APP/PS1 mice (Li and Liu, 2010). However, the number of apoptotic cells was greatly diminished after SRPK2 depletion (0.13 ± 0.03 % of neurons in DG, n=3) (Fig 5C, lower right panel). In contrast, no active caspase 3-positive cells were
detected in neither LV-GFP nor LV-shSRPK2-injected WT mice (Fig 5B, upper panels), suggesting SRPK2 is responsible for neuronal apoptosis in pathological conditions only. We have also tested if SRPK2 depletion in vivo alters the tau hyperphosphorylation in APP/PS1 brain. As shown in Fig 5C, the amount of PHF-tau was increased in APP/PS1 DG, which was reduced after LV-shSRPK2 infection. To further demonstrate SRPK2 plays an active role in promoting tau aggregation through phosphorylation, we infected cultured neurons with LV-myc-SRPK2 WT or LV-myc-SRPK2 KD. While wild-type SRPK2 significantly increased the amount of tau aggregates, neurons with SRPK2 KD overexpression had no effect on the amount of cellular tau aggregates (Fig 5D). Thus, SRPK2 is important to promote tau phosphorylation both in vitro and in vivo.

SRPK2 inhibits tau-dependent microtubule polymerization and neurite outgrowth

To investigate whether SRPK2 modulates tau’s function in assisting microtubule polymerization, we carried out an in vitro microtubule polymerization assay using purified tubulins in the presence of various recombinant tau proteins. In this assays, tau was phosphorylated by SRPK2 before incubation with tubulin. While non-phosphorylated tau strongly promoted microtubule assembly, SRPK2-phosphorylation on tau substantially inhibited the polymerization (Fig 6A). We have also assessed the ability of various tau phosphorylation mutants in assisting tubulin polymerization. As expected, tau S214E mutant that mimics the phosphorylation of tau on S214 compromised tau’s ability to promote tubulin polymerization (Fig 6B). Since tau is an important factor in promoting axon elongation (Shea et al., 1992), we wondered if overexpressing SRPK2 alters the axon elongation in intact cells. We transfected primary neurons with GFP, GFP-SRPK2-WT or GFP-SRPK2-KD at DIV7 for 24 h. The neurons were then stained with the axon marker (anti-Tau-1 antibody) and the length of primary neurites was analyzed. We observed that overexpression of SRPK2 significantly reduced the axon length compared with that of GFP transfected cells (Fig 6C). Consistently, overexpression of wild-type tau in primary neurons potently enhanced the axon length, which was partially decreased in tau S214E transfected cells (Fig 6D). These data are in good agreement with the observation that SRPK2 phosphorylation reduced tau-mediated microtubule polymerization in vitro. In human, intracellular accumulation of PHF-tau disrupts the cytoskeleton and contributes to axonal and dendritic degeneration. It has been reported that dendrite densities are reduced by 60% in AD hippocampus (Falke et al., 2003). If SRPK2 is a physiological kinase that promotes tau aggregation during AD progression, depletion of SRPK2 should alleviate the number of damaged dendrites in APP/PS1 mice. Similar to the report in human study (Falke et al., 2003), the dendrite density was greatly reduced in APP/PS1 DG as revealed by MAP2 staining (Fig 6E, lower left). Significantly, the number of dendrite was increased after SRPK2 depletion in APP/PS1 mice (Fig 6E, lower right), strongly suggesting that activation of SRPK2 in AD crumbles the neuronal morphology. Hence, SRPK2 phosphorylation of tau regulates its role in assisting microtubule polymerization and neurite elongation.

DISCUSSION

SRPKs recognize SR repeats and phosphorylate serine in the SR proteins (Koizumi et al., 1999; Daub et al., 2002; Mathew et al., 2008). In addition to acting as a modifier of cell cycle progression and apoptotic pathways (Jang et al., 2008; Jang et al., 2009; Hong et al., 2011), our findings demonstrate that SRPK2 is a negative regulator of neuronal functions in AD, possibly through modulating the phosphorylation of tau. Surprisingly, SRPK2 phosphorylates tau S214 following the proline residue but not the adjacent SRSR consensus repeat, indicating that SRPK2 may also phosphorylate unconventional sites like the “PSPLP” in tau (Fig 4E). In addition, SRPK2 binds to tau protein through the spacer region (aa 384-438) preceding the second kinase domain (Fig 3F), which fits with our previous
observation that this region is responsible for cytoplasmic localization of SRPK2 (Hong et al., 2011). Removal of the unique spacer between the two kinase domains in SRPK has little effect on the kinase activity but triggers its nuclear translocation to induce aggregation of splicing factors in the nucleus (Ding et al., 2006). Interestingly, this region is an intrinsically disordered motif that shares little homology between SRPK2 and SRPK1 (Wang et al., 1998; Plocinik et al., 2011). Thus, it remains unclear why tau associates with both SRPKs on a region that is structurally different between the two isoforms (Fig 3B). A possible explanation is that the structural conformations of the SRPK regions for tau association are similar although the primary amino acid sequences are not well conserved.

While most neurons are terminally differentiated that remain in non-dividing G0 phase, aberrant cell cycle reactivation provokes neuronal cell death (Yang and Herrup, 2007; Lee et al., 2009b). In AD neurons, cell cycle regulators like cyclin D, Cdk4 and PCNA are significant elevated, indicating that dysregulation of these components is a contributor to the death of specific neurons in AD (Busser et al., 1998; Lee et al., 2009a). Interestingly, tau phosphorylation is also a cell cycle-regulated event that tau S214 is prominently phosphorylated during metaphase (Illenberger et al., 1998). Phosphorylation of this residue strongly decreases the tau-microtubule interaction in vitro and suppresses microtubule assembly (Fig 6), suggesting the phosphorylation is a key event in the detachment of tau from microtubules during mitosis. Since SRPK2 mediates post-mitotic neurons to re-enter the cell cycle by triggering cyclin D1, Cdk4 and cyclin B1 expressions (Jang et al., 2009) and that depletion of SRPK2 in APP/PS1 brain suppresses neuronal apoptosis (Fig 5B), our finding that SRPK2 is activated in AD neurons thus identifies a key molecule in linking the cell cycle, tau hyperphosphorylation and neuronal death.

Tau phosphorylation can be recognized by antibodies against multiple epitopes such as the famous AT100, PHF and AT8 (Hampel et al., 2010). Formations of these pathological tau epitopes need serial phosphorylations of tau at different sites. For instance, the generation of AT100 epitope needs the sequential phosphorylation of tau at S214 then T212 and T217 (Yoshida and Goedert, 2006). We have identified SRPK2 is a novel tau kinase that phosphorylates tau at S214, suggesting it may initiate the hyperphosphorylation of tau and work in concert with other tau kinases to form pathological tau epitope in vivo. Indeed, we found that the PHF-tau in the APP/PS1 DG was reduced after SRPK2 depletion, which further supports the notion that SRPK2 plays a critical role for tau aggregation. It is interesting to note that phosphorylation of tau on S262 and S214 not only detaches it from microtubules but also protects it from aggregation into PHF in vitro (Schneider et al., 1999), which is in contrast to the general believe that abnormal phosphorylation of tau should promote its aggregation in PHF. However, controversial observations have also been reported. For example, Necula and Kurset observed that pseudophosphorylation mutant of tau (S214E) increased tau fibrillization in vitro (Necula and Kuret, 2004). Similarly, Pei et al proposed that phosphorylation of tau on S214 neutralizes the protective effect of S262 phosphorylation and thus causes the self-assemble of tau into filaments (Pei et al., 2006). Therefore, the specific role tau S214 on PHF formation is still unclear but our observation that phosphorylation of tau by SRPK2 favors the formation of PHF in mice. It is noteworthy that tau S214 could be phosphorylated by multiple kinases including PKA and GSK (Scott et al., 1993; Liu et al., 2002). Inhibition of these kinases in neurons resulted in reduced tau S214 phosphorylation (Fig 4K). When SRPK2 is overexpressed, tau phosphorylation is robustly increased. Inhibition of PKA and CDK5 somehow reduced tau S214 phosphorylation by SRPK2. Remarkably, SRPK2 overexpression failed to increase tau S214 phosphorylation when GSK3 activity was suppressed, suggesting GSK3 could also modulate the SRPK2-induced tau S214 phosphorylation in addition to acting as a tau kinase per se. Surprisingly, inhibition of CDK5 in control virus-infected neurons by roscovitine did not reduce tau S214 phosphorylation, although CDK5 can phosphorylate tau on S214 in vitro.
Presumably, the tau phosphorylation is counter-balanced by the activation of extracellular signal-regulated kinase (ERK, another tau S214 kinase), which is the consequence of CDK5 inhibition (Zheng et al., 2007; Kim et al., 2011).

Tauopathy is a group of disorders characterized by the accumulation of hyperphosphorylated tau protein in the brain, resulting in dementia (Shiryaev et al., 2010). Therefore, abnormal tau accumulation in APP/PS1 mice causes a poor performance in memory task like Morris water maze as showed in the current study. Interestingly, SRPK2 depletion alleviates the behavioral deterioration in APP/PS1 mice (Fig 2C). The results suggest that activation of SRPK2 may promote the behavior deterioration in APP/PS1 mice. Our electrophysiology studies also show that the LTP is significantly impaired in APP/PS1 mice, whereas SRPK2 silencing rescues the defective synaptic plasticity (Fig 2D). In addition, averaged PPF amplitude in LV-GFP injected APP/PS1 mice is lower than the WT animals under the same virus treatment, but is significantly increased in LV-shSRPK2 infected APP/PS1 mice, indicating SRPK2 depletion rescues the presynaptic neuronal functions and improves synaptic plasticity in APP/PS1 mice (Fig 2E). Since tau is an important protein in maintaining the morphological integrity and synapse density of neurons (Perez-Cruz et al., 2011), presumably, the impaired synaptic function in APP/PS1 mice is a result of reduced dendritic arborization, which could be rescued by SRPK2 inactivation (Fig 6E). Together, our results support that tau is an important target of SRPK2 in neurons and modulation of the SRPK2/Tau signaling pathway may represent a promising strategy to prevent neuronal cell death or malfunction during the progression of AD.

Acknowledgments

The work is supported by a grant from NCI, NIH (NS060680) to K.Y and NIA, NIH (AG028679) to H.-g. L. The authors thank the Viral Core Facility of Emory University and Dr. Xingping Huang who provided the lentiviral vectors and HEK293FT cells, and the Rodent Behavioral Core of Emory University School of Medicine for performing the water maze test. We also thank Dr. Xiang-Dong Fu (UCSD) for his critical reading and comments on this manuscript.

REFERENCES


Figure 1. SRPK2 is activated in AD brains

(A) Increased SRPK2 T492 phosphorylation in APP/PS1 mice. Western blot analysis using specific antibodies as indicated was performed in cell lysates collected from the cortex of 4 to 12-month-old wild-type and APP/PS1 mice.

(B) Increased SPRK2 T492 (upper panels) phosphorylations on APP/PS1 (9-month-old) cortex. Immunohistochemical staining was performed in paraffin embedded brain sections (8 μm) using various antibodies as indicated. The expression of SRPK2 (lower panels) was also shown. Scar bar represents 20 μm.

(C to E) In 3xTg-AD mice, phospho-SPRK2 T492 signals are found in CA1 neurons (D), where they parallel with the PHF-Tau (AT-8) (E). A higher magnification of the indicated area in (C) is shown in (D). Scale bar = 50 μm.

(F) Phospho-SRPK2 T492 immunoreactivities were co-localized with those of PHF-tau (indicated by white arrows) in 3xTg-AD hippocampus. Scale bar = 10 μm.

(G to I) The immunoreactivity of phospho-SRPK2 T492 is upregulated in the cytoplasm of pyramidal neurons in the hippocampus of AD-affected individuals (H) when compared to control brain (G). Phospho-SRPK2 T492 is observed in NFT-bearing neurons (black arrow), GVD bearing neurons (arrowhead) and Hirano body (white arrow). A higher magnification of the inset of H is shown in (I).

(J) Phospho-SRPK2 T492 co-localizes with PHF-tau (AT8) in neurons of human AD brains.
Figure 2. Knockdown SRPK2 expression improves synaptic plasticity in APP/PS1 mouse

(A) APP/PS1 mice were injected with LV-shSRPK2 into the DG region. After 2 weeks, the mice were euthanized and the brains were perfused and fixed in 4% paraformaldehyde. The brains were then sectioned (40 μm) and expression of GFP (an indication of infection) was examined under fluorescent microscopy.

(B) Western analysis of SRPK2 expression in lentivirus injected hippocampus. Two weeks after LV-GFP or LV-shSRPK2 injection, the hippocampus of the mice were collected and used for immunoblotting.

(C) Percentage of time that the animals spent in the platform quadrant of the water tank during the probe trial of the Morris water maze test (*: P<0.05, Student’s t-test, n=5).

(D) Synaptic plasticity in hippocampus was studied by inducing long-term potentiation at the mossy fiber-CA3 synapse of WT or APP/PS1 brains infected with LV-GFP or LV-shSRPK2 (○: WT-LV-GFP, ▼: APP/PS1-LV-GFP, ▲: APP/PS1-LV-shSRPK2, n=6, *: P<0.05, Two-way ANOVA). Examples of single trance recordings from WT mice before (1) and after LTP induction (2) were also shown.

(E) Paired pulse facilitation (PPF) was examined in WT or APP/PS1 brains infected with LV-GFP or LV-shSRPK2 in the dentate gyrus at an interpulse interval from 10 to 500 ms (○: WT-LV-GFP, ▼: APP/PS1-LV-GFP, ▲: APP/PS1-LV-shSRPK2, n=6, **: P<0.01, Two-way ANOVA).
Figure 3. Tau binds SRPK2 in vitro and in vivo

(A) SRPK2 interacts with tau in SH-SY5Y neuroblastoma cells. Cell lysates from SH-SY5Y were incubated with control IgG or anti-Tau-1 antibody, followed by immunoprecipitation. The precipitated proteins were resolved on SDS-PAGE, and detected with anti-SRPK2 antibody (top panel). Inputs of SRPK2 (middle panel) and tau (bottom panel) were also examined.

(B) SRPK2 and SRPK1 interact with tau in mouse brain. Brain lysates collected from WT or APP/PS1 mouse brain were subjected to immunoprecipitation using anti-SRPK1 or anti-SRPK2 antibody. The precipitated proteins were analyzed with Western blot and detected by anti-Tau antibody (1st panel). Inputs of SRPK2 (2nd panel), SRPK1 (3rd panel) and tau (4th panel) were also shown.

(C) Tau binds to SRPK1 and SRPK2. GST or GST-Tau was transfected into 293 cells. The cell lysates were subjected to GST pull-down and detected with anti-SRPK1 or anti-SRPK2 antibody. Expressions of GST proteins (middle panel) and SRPKs (bottom panel) were also shown.

(D) Schematic diagram of various tau truncation mutants used in the in vitro binding assay.

(E) SRPK2 interacts with the proline rich region of tau protein. Recombinant GST-Tau fragments purified from bacteria were incubated with cell lysates from HEK293 cells. The GST proteins were then pull-downed using glutathione beads and the co-precipitated SRPK2...
proteins were detected using anti-SRPK2 antibody (upper panel). The expression of various tau fragments was also analyzed (lower panel).

(F) Schematic diagram of various SRPK2 truncation mutants used in the *in vitro* binding assay.

(G) SRPK2 interacts with tau through the region prior to the second kinase domain. Various GST-tagged SRPK truncation mutants were transfected into HEK293 cells. After 24 h, the cells were infected with adenovirus overexpressing tau for 24 h. GST pull-down assay was then performed and the precipitated proteins were analyzed by Western-blot with anti-Tau antibody (top panel). The expression of tau (middle panel) and SRPK2 fragments (bottom panels) were also examined.
Figure 4. Tau is the physiological substrate of SRPK2

(A) Wild-type SRPK2 affects the phosphorylation of tau in HEK293 cells. GST-Tau was co-transfected with empty vector, myc-SRPK2 WT, or myc-SRPK2-KD into HEK293 cells. Forty eight h after transfection, cell lysates were collected and analyzed by Western blot with anti-GST-HRP or anti-myc antibody. Migration of tau was slower in myc-SRPK2 WT over-expressed sample (upper panel). Expression of the SRPK mutants were also verified (lower panel).

(B) SRPK2 phosphorylates tau in vitro. Bacterial expressed and purified GST-Tau was incubated with GST-SRPK2 WT, GST-SRPK2 KD, GST-SRPK2 T492D, or GST-SRPK2 T492A in the presence of [$\gamma^{32}$P]-ATP. The reaction products were separated in SDS-PAGE and analyzed by autoradiography (upper panel). The protein inputs were shown using Coomassie blue staining (lower panel).

(C and D) SRPK2 phosphorylates tau on the proline-rich region. Various tau truncates (C) were bacterially expressed, purified and incubated with recombinant GST-SRPK2 in the presence of [$\gamma^{32}$P]-ATP. The reaction products were separated in SDS-PAGE and revealed by autoradiography (D). SRPK2 dramatically phosphorylates the tau truncates containing the proline-rich region. The protein inputs were also shown.

(E) Schematic diagrams of the potential SRPK2 phosphorylation sites in tau.

(F) SRPK2 phosphorylates tau on S214 residue. Various GST-tagged tau point mutants were bacterially expressed, purified and then incubated with recombinant GST-SRPK2 in the presence of [$\gamma^{32}$P]-ATP. The reaction products were separated in SDS-PAGE and the phosphorylation was visualized by autoradiography (upper panel). The proteins input were analyzed by Coomassie blue staining (lower panel).

(G) Overexpression of SRPK2 upregulates tau phosphorylation on S214. Primary neurons were infected with LV-GFP, LV-myc-SRPK2 WT, or LV-myc-SRPK2 KD for 72 h. Tau phosphorylation was monitored using anti-phospho-Tau S214 antibody (top panel).
Expressions of Tau (middle panel), SRPK2 WT and SRPK2 KD were verified by anti-myc antibody (bottom panel).

(H) Depletion of SRPK2 reduces tau phosphorylation on S214. Primary neurons were infected with lentivirus expressing control shRNA (LV-con shRNA) or shSRPK2 for 48 h. The cell lysates were resolved by SDS-PAGE, and the knockdown efficiency was examined using anti-SRPK2 antibody (1st panel). Reduced expression of SRPK2 also inhibited tau phosphorylation on S214 (2nd panel). The expressions of total tau (3rd panel) and tubulin were also shown (4th panel).

(I) Overexpression of SRPK2 in primary neuron induces tau phosphorylation on S214. Primary mouse neurons (P1) were infected with LV-myc-SRPK2 at DIV7 for 72 h. After fixation in 4% paraformaldehyde, the cells were co-stained with anti-myc and anti-phospho-Tau S214 antibodies. By comparing with the non-infected cells (white arrow), overexpression of SRPK2 (yellow triangle) significantly enhanced the phosphorylation of tau on S214.

(J) Depletion of SRPK2 inhibited tau phosphorylation on S214. Primary mouse neurons (P1) were infected with adenovirus expressing shSRPK2 at DIV7 for 72 h. The cells were fixed and immunostained with anti-phospho-Tau S214 antibody. Phosphorylation of tau S214 was reduced in the virus-infected cells (yellow triangle) when compared with the non-infected cells (white arrow).

(K) SRPK2-induced tau S214 phosphorylation is implicated with GSK3. Cortical neurons (DIV7) were infected with LV-GFP or LV-SRPK2 WT for 48 h, followed by 10 μM H89 (PKA inhibitor), roscovitine (CDK5 inhibitor) or SB216763 (GSK3 inhibitor) stimulation for 6 h. Phosphorylation of tau S214 was then monitored by immunoblotting.
Figure 5. SRPK2 promotes tau hyperphorylation

(A) Depletion of SRPK2 reduces tau S214 phosphorylation in APP/PS1 DG. Immunohistochemical staining of tau S214 phosphorylation was performed in LV-GFP or LV-shSRPK2 virus infected DG in WT or APP/PS1 mice. Examples of cells showing positive signal were indicated by arrows. Scale bar represents 50 μm.

(B) Depletion of SRPK2 reduces apoptosis in APP/PS1 DG. Immunohistochemical staining of active caspase 3 was performed in LV-GFP or LV-shSRPK2 virus infected DG of WT or APP/PS1 mice. Examples of cell showing positive signal were indicated by arrows. Scale bar represents 25 μm.

(C) Depletion of SRPK2 reduces the amount of PHF-tau in APP/PS1 DG. Immunohistochemical staining of PHF-tau using AT8 antibody was performed in LV-GFP or LV-shSRPK2 virus infected DG of WT or APP/PS1 mice. Examples of cell showing positive signal were indicated by arrows. Scale bar represents 50 μm.

(D) Overexpression of SRPK2 promotes tau aggregation in primary neurons. Primary rat neurons (DIV10) were infected with LV-GFP, LV-myc-SRPK2, or LV-SRPK2-KD for 48 h. The amount of tau in different cellular fractions were separated by ultracentrifugation, detected by western blot analysis and densitometrically quantified (1st panel, P<0.05, Student t-test, n=3). Expressions of various SRPK2 mutants (4th panel), cytosolic tau (2nd panel), aggregated tau (3rd panel) and tubulin (5th panel) were also examined.
Figure 6. SRPK2 inhibits tau-dependent microtubule polymerization and neurites outgrowth

(A) SRPK2 phosphorylation inhibits tau-promoted microtubule polymerization. Recombinant GST-Tau or GST-Tau S214A was first incubated with purified GST or GST-SRPK2 to promote tau phosphorylation. The reaction products were then incubated with purified bovine brain tubulin. The formation of microtubule was monitored by measuring the absorbance in a spectrophotometer at 350 nm (open square: Tau WT + GST; solid square: Tau WT + SRPK2; grey square: Tau S214A + SRPK2).

(B) Tau S214E mutant fails to promote microtubule polymerization in vitro. GST, GST-Tau, GST-Tau S214A or GST-Tau S214E recombinant protein was incubated with purified bovine brain tubulin. The turbidity of polymerized microtubule was measured at 350 nm (open square: GST; solid square: GST-tau; grey square: GST-Tau S214A; grey circle: GST-tau S214E).

(C) SRPK2 represses axon elongation in primary neurons. Primary neurons (DIV 7) were transfected with GFP, GFP-SRPK2 WT, or GFP-SRPK2 KD for 24 h. The cells were then fixed and immunostained using anti-Tau-1 antibody to display the axons. The lengths of the primary neurites were measured. Expression of SRPK2 significantly inhibited the axonal growth of primary neuron (***: P<0.001, Student’s t-test, n=20). Scale bar represents 200 μm.

(D) The ability of tau to promote axon elongation in primary neuron was decreased by S214E mutation. Primary neurons (DIV 7) were transfected with GFP, GFP-Tau, or GFP-Tau S214E for 24 h. The cells were then fixed and the images of the transfected neurons were captured under fluorescent microscope. Overexpression of wild-type tau significantly...
enhanced the axonal elongation (***: P<0.001, Student’s t-test, n=20). Scale bar represents 200 μm.

(E) Increased neurite density in SRPK2-depleted APP/PS1 mice. The dendrites of cells in various virus-infected DG were stained using anti-MAP2 antibody. Scale bars represent 50 μm.